Terrie Curran insider trades

Open-market stock purchases and sales by Terrie Curran, Director at Arcutis Biotherapeutics, Inc, from SEC Form 4 filings since Nov 15, 2016.

Track record: 0% of 2 scored buys are up 5% or more since purchase, averaging -8%.

Recent trades

DateStockTradeValue
Aug 27, 2026ARQT Arcutis Biotherapeutics, IncBought (not open market)$83.7K
Aug 27, 2026ARQT Arcutis Biotherapeutics, IncSold$279K
Aug 27, 2026ARQT Arcutis Biotherapeutics, IncBought (not open market)$233K
Aug 27, 2026ARQT Arcutis Biotherapeutics, IncSold$677K
Aug 27, 2026ARQT Arcutis Biotherapeutics, IncBought (not open market)—
Aug 27, 2026ARQT Arcutis Biotherapeutics, IncBought (not open market)—
Aug 20, 2026ARQT Arcutis Biotherapeutics, IncBought (not open market)$8.1K
Aug 20, 2026ARQT Arcutis Biotherapeutics, IncSold$27.9K
Aug 20, 2026ARQT Arcutis Biotherapeutics, IncBought (not open market)—
Jun 5, 2026ARQT Arcutis Biotherapeutics, IncBought (not open market)—
Jun 5, 2026ARQT Arcutis Biotherapeutics, IncBought (not open market)—

Companies traded

  • ARQT Arcutis Biotherapeutics, Inc: 4 sales, last Aug 27, 2026
  • PHAT Phathom Pharmaceuticals, Inc: 2 buys, 8 sales, last Feb 27, 2025
  • MYOV Myovant Sciences Ltd: 3 sales, last Mar 10, 2023
  • CELG Celgene Corp /de/: 3 sales, last Nov 20, 2019

Get free alerts when Terrie Curran files a new trade →